UK regulators would likely have to fight to win jurisdiction over the $100 billion merger review of pharmaceutical giants Pfizer and AstraZeneca, according to competition experts.
The deal is so large, according to reports, that the European Commission would likely intervene if the UK’s Competition and Markets Authority tried to take control of the investigation.
Pfizer has offered $106 billion to acquire the pharma rival, but AstraZeneca has reportedly rejected the bid. A deal could still be struck, reports say, as Pfizer appears to be willing to increase its offer.
According to reports, UK Prime Minster David Cameron said he would like to see significant concessions from Pfizer before allowing the two to merge, but competition lawyers told reporters that should Cameron intervene in the deal, the Commission would likely take over.
Full content: Chicago Tribune
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Walmart Withdraws and Refiles Antitrust Review Application for Vizio Acquisition
Mar 28, 2024 by
CPI
Apple Prevails in Dismissal of Crypto-Payment Antitrust Lawsuit
Mar 27, 2024 by
CPI
Amazon Fined in Poland for Misleading Customers
Mar 27, 2024 by
CPI
Credit Card Rewards Under Threat as Visa, Mastercard Settlement Impacts Swipe Fees
Mar 27, 2024 by
CPI
UK Fashion Giants Commit to Honest Environmental Claims
Mar 27, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI